Sino Biopharmaceutical Limited
SBHMYOTCHealthcare● Active
$12.98
$-1.96(-13.12%)
Market Cap$11.6B
P/E Ratio—
52W High$20.16
52W Low$9.48
Sino Biopharmaceutical Limited (SBHMY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SBHMY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $30.97B | $28.87B | $26.20B | $26.03B | $26.86B |
| Cost of Revenue | $5.55B | $5.34B | $4.99B | $5.80B | $5.33B |
| Gross Profit | $25.41B | $23.53B | $21.21B | $21.54B | $21.53B |
| Gross Margin %(computed) | 82.07% | 81.51% | 80.95% | 82.76% | 80.15% |
| Operating Expenses | |||||
| R&D Expenses | $5.71B | $5.23B | $4.47B | $4.33B | $3.75B |
| G&A Expenses | $0.00B | $2.08B | $1.87B | $2.20B | $2.19B |
| Total Operating Expenses | $18.79B | $17.39B | $15.54B | $15.95B | $17.19B |
| Operating Income | $6.63B | $6.14B | $5.79B | $5.59B | $5.08B |
| Operating Margin %(computed) | 21.40% | 21.26% | 22.08% | 21.46% | 18.91% |
| Interest Income | $0.62B | $0.50B | $0.19B | $0.20B | $0.16B |
| Interest Expense | $0.27B | $0.30B | $0.50B | $0.43B | $0.31B |
| Income Before Tax | $6.75B | $5.28B | $5.41B | $5.21B | $18.57B |
| Income Tax Expense | $1.58B | $0.49B | $0.80B | $0.70B | $1.96B |
| Net Income | $2.28B | $3.50B | $2.33B | $2.54B | $14.61B |
| Net Margin %(computed) | 7.36% | 12.12% | 8.90% | 9.77% | 54.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.60 | $4.00 | $1.58 | $2.20 | $15.60 |
| Wtd Avg Shares | 0.90B | 0.86B | 1.17B | 0.93B | 0.94B |
| EBITDA | $7.78B | $6.11B | $6.98B | $6.69B | $19.87B |
| EBITDA Margin %(computed) | 25.12% | 21.16% | 26.64% | 25.71% | 73.99% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Sino Biopharmaceutical Limited data
About Sino Biopharmaceutical Limited (SBHMY) Income Statement
Sino Biopharmaceutical Limited (SBHMY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SBHMY reported revenue of $30.97B, gross profit of $25.41B (gross margin 82.07%), and net income of $2.28B — a net profit margin of 7.36%.
Frequently asked questions
SBHMY · 4 questionsSino Biopharmaceutical Limited (SBHMY) reported revenue of $30.97B for 2025, up 7.3% year-over-year.
SBHMY revenueSBHMY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09